作者: Wen-ting Yang , Xia-wei Zheng , Shuang Chen , Chun-shuo Shan , Qing-qing Xu
DOI: 10.1016/J.BCP.2017.07.002
关键词: Donepezil 、 Dementia 、 Pharmacology 、 Placebo 、 Traditional Chinese medicine 、 Neurogenesis 、 Oncology 、 Randomized controlled trial 、 Internal medicine 、 Medicine 、 Adjuvant therapy 、 Adverse effect
摘要: Currently, there is lack of cure or disease-modifying treatment for Alzheimer's disease (AD). Chinese herbal medicine (CHM) purported to ameliorate AD progression, perhaps by promoting hippocampal neurogenesis. Here, we conducted an updated systematic review investigate the efficacy and safety CHM based on high-quality randomized controlled trials (RCTs) reviewed its possible mechanisms neurogenesis according animal-based researches. Twenty eligible studies with 1767 subjects were identified in eight database searches from inception February 2017. The investigated versus placebo (n=3), donepezil (n=9 10 comparisons), plus a basic (n=2). Adverse events reported 11 studies, analyzed but not observed 3 6 studies. main findings present study are that as adjuvant therapy exerted additive anti-AD benefit, whereas monotherapy was inconclusive. Additionally, CHMs generally safe well tolerated patients. Active molecules frequent constituents can alter multiple critical signaling pathways regulating Thus, evidence supports, limited extent, conclusion be recommended routine use patients mechanism enhances adult through activating multi-signal pathways.